Elevation breathes $17m deeper as PhII COPD candidate EP-101 improves expiration
This article was originally published in Clinica
Executive Summary
Elevation Pharmaceuticals, a respiratory diseases start-up, says that its investigational aerosol, EP-101, significantly improved forced expiratory volume in one second (FEV1) 24 hours post dosing versus placebo (p<0.001)>0.001)>